Inaktiver Wert

Andere Sprachen Apyx Medical Corp Nasdaq

Aktien

US03837C1062

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024	25.04.
APYX MEDICAL CORPORATION SHOWCASES NEW DATA AND TREATMENT INSIGHTS AT THE RENUVION USERS' SUMMIT	12.04.
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit	11.04.
Archon Capital Management Engages with Apyx Medical Corporation	05.04.
Stavros G. Vizirgianakis Engages in Discussions with Apyx Medical Corporation	01.04.
APYX MEDICAL CORPORATION REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS, INTRODUCES FULL YEAR 2024 FINANCIAL OUTLOOK	22.03.
Apyx: Q4 Earnings Snapshot	21.03.
Apyx Medical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook	21.03.
Apyx Medical Corporation Provides Earnings Guidance for the Year Ending December 31, 2024	21.03.
Apyx Medical Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.03.
North American Morning Briefing : Investors -2-	21.03.
Apyx Medical Corporation to Release Fourth Quarter and Fiscal Year 2023 Financial Results on March 21, 2024	04.03.
APYX MEDICAL CORPORATION ANNOUNCES RENUVION TO BE FEATURED IN EDUCATIONAL SESSIONS AT THE AMERICAN ACADEMY OF COSMETIC SURGERY SCIENTIFIC MEETING	22.02.
Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting	21.02.
APYX MEDICAL CORPORATION ANNOUNCES PEER-REVIEWED CLINICAL PUBLICATION EVALUATING THE SAFETY OF RENUVION FOLLOWING LIPOSUCTION IN MULTIPLE AREAS OF THE BODY	23.01.
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body	22.01.
Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body	22.01.
Apyx Medical Reports Q4, Full-Year 2023 Preliminary Revenue	08.01.
Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Apyx Medical Corp Nasdaq

Aktien

US03837C1062

Andere Sprachen

Filter